July 2023 Vol 16, No 4 – Online Only

Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, Director, Yale Cancer Center, and Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven, CT, and ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes. Read More ›

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results of the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 17, 2023, and June 15, 2023. Read More ›

At the Association of Community Cancer Centers 49th Annual Meeting & Cancer Business Summit, Andre Harvin, PharmD, MS, MBA, Executive Director of Pharmacy, Oncology Services, Cone Health Cancer Center, Greensboro, NC, presented a keynote lecture titled, “Robots, Biologics, and Advocates: Lessons from the Pharmacy.” Read More ›

On June 20, 2023, the FDA approved a new indication for talazoparib, an oral poly (ADP-ribose) polymerase inhibitor, in combination with enzalutamide for homologous recombination repair gene mutation–positive, metastatic castration-resistant prostate cancer. Read More ›

Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study. Read More ›

Sarcoma is a general term used to describe a broad group of rare malignancies that develop in the body’s bone and connective tissue, such as fat, muscle, nerves, blood vessels, and the tissue that surrounds bones and joints. It is frequently referred to as the “forgotten cancer” because it comprises a very small percentage of all adult cancers. Read More ›

A new study has found that partners of colorectal cancer survivors experienced long-term financial toxicity that was associated with worse health-related quality of life due to systems- and individual-level behavioral factors. Read More ›

Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. Read More ›